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Nociceptive Inflammatory Neuropathic 
! Opioid peptides are key role players in modulation of pain ! 
“ Pain is an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage. (The International Association for the 
Study of Pain)” 









Endogenous + externally administered 
 
           + other systems (e.g. CB)  
Ref. 
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OPIOID PEPTIDES   
WIDE RANGE OF PHARMACOLOGICAL 
RESPONSES: 
 
Pain and analgesia 
Stress and anxiety  
Tolerance and dependence  
Learning and memory 
Eating and drinking 
Endocrinology 
Mental illness and mood  
Neurological disorders 
Neurophysiology 
Gastrointestinal, renal and hepatic functions 
Cardiovascular 
Immunological 
Localization of opioid receptor expression 
INTRODUCTION  
MOR: µ1, µ2, µ3  
 
KOR: κ1, κ2 
 









•  Pain perception 
 
•  Pain modulation: 
 
 Peripheral pain control          
 Central modulation of pain 
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Molecular recognition of opioid ligand-receptor interactions: 
In silico research. 
 
             MESSAGE-ADDRESS CONCEPT 
Nonselective 
S. Granier et al., Nature, 485 (2012) 400-404. 
H. Wu et al., Nature, 485 (2012) 327-332. 



































MOR: polar interaction 
KOR: salt bridge interaction 





























































Molecular recognition of opioid ligand-receptor interactions: In silico research. 
 







Endomorphin-1 Tyr Pro Trp Phe-NH2
Dynorphin(1-8) Tyr Gly-Gly Phe Leu-Arg-Arg-Ile





































Two types of endogenous peptides – message sequence: 
 
1. Tyr-Gly-Gly-Phe  
 Enkephalins, endorphins, dynorphins  
2. Tyr-Pro-Phe/Trp  
  Endomorphins 
 
Structural constraints in message 





B.L. Podlogar et al.,FEBS Lett, 439 (1998) 13-20.     M.R. Hutchinson et al., J Neurosci, 32 (2012)  11187-11200.    
    
Structure-activity/selectivity relationship for opioid receptors. 
IN-SILICO 
1. Structural characteristics determine activity 
μ-Selective 
Pocket 
Altered opioid reward behavior 
2. Interplay with other receptors 
 
• Binding to other receptors, e.g. TLR4/MD2 
Docking of remifentanyl and its metabolite 
• Heterodimerization: 
  Change the endocytosis/recycling kinetics receptor 
 Allosterically enhancment of ligand binding capacities of 
the other partner 
 Functional modulation signaling pathways 
Dual  μ-agonist/δ-antagonist profile of TIPP-NH2 









In vitro opioid receptor binding assays: peptide purity level. 
! Peptide quality: not assured/maintained ! 
Van Dorpe S. et. al., J Bioanal Biomed, 2011, doi: 10.4172/1948-593X.S6-003. 


















46 peptides from one supplier (PPR) 
 
CoA specification ≥ 90 % HPLC purity 
 
















Also: 1 peptide 
from ≠ suppliers: 
problematic! 
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Specific binding  
 
Labelling Relatively poor sensitivity 





















by MOR agonists 
 
J.J. Ballesta, BJP, 2012 
Binding 
characterization of  
linear, cyclic 
monomer and dimer 
of enkephalin 
 
D.H. Kim, BKCS, 2012 




Label-free and no immobilization 
Ligand or protein size – no 
limitation 
All binding parameters in one 
experiment 
Requires relatively high [sample] 
   
Complexation of the 
opioid peptide 
tynorphin and dipeptidyl 
peptidase III (ΔS 
dominated process) 
 








Mass of the analyte 
IN VITRO 
Nano ITC, e.g. analysis 
of Binding Organic 
Compounds to 





New RLB method to 
measure the  
concentration of non-
radiolabeled drugs in 
the brain (ex vivo) 
 
G. P. Hussmann, JPET, 2012 
 
Characterization of  
stability of backbone 
hydrogen (using a newly 
developed pressure cell 
Nisius and Grzesiek) 
 
L. Nisius, Nature, 2012 
 
Real-time kinetic 
analysis of KD-value for 
label-free therapeutic 








•  Isolated tissues for opioid activity: 
 
 Mouse vas deferens (δ >> μ > κ) 
 Guinea pig ileum (μ > κ >> δ) 
 
•  Advantages: 
 Relatively small amount of test material 
 Tissue responses (incl. adsorption, 
penetration, metabolization) 
 Identification receptor target using antagonists 
 
•   Disadvantages: 
 Non-specific binding 
 Adsorption to glass  
 
•  Advances – mimicing in-vivo functionality: 
 Bi-ventricular working heart system 
 Whole lung decellularization/recellularization 
chamber for regenerative medicine 










> 95 % 
 purity 
    
           
             
           
                 
           
             
           
             
Guinea pig ileum 
QUALITY OF PEPTIDES IS AN IMPORTANT ASPECT  
TO AVOID FALSE FUNCTIONALITY CONCLUSIONS 
Impurity profile of peptides            
 
M. Verbeken et al., Anal Biochem, 421 (2011) 547-555. 
N/A: not applicable, as only one peak is observed due to the main peak present 
Test sample: 10 min exposure to tissue organ bath with isolated guinea pig ileum  





Pain managment within the CNS:  Opioid peptides should cross the BBB.            
MOR main target pain management: Pharmacokinetic properties 
Opioid: 
• Serum stability 
• Free vs. bound 
 
Brain distribution mechanisms: 
• Metabolic clearance (t1/2 brain) 
• Plasma protein binding (Free 
vs. bound) 
• Non specific binding 
• Clearance to ECF and CSF 
BBB penetration mechanisms: 
• Influx (Kin, PS, P) 
• Efflux (Kout, t1/2 brain) 
 
 
S. Van Dorpe et al., Brain Struct Funct, 217 (2012) 687-718. 













S. Van Dorpe et al., Brain Struct Funct, 217 (2012) 687-718. 
1 technique: ≠  responses 
1 response: ≠ techniques 
Correlation 
Penetration =  
Permeation (rate): Papp, Kin 
+ 
Distribution (extent): B/P, Kp 






S. Van Dorpe et al., Brain Struct Funct, 217 (2012) 687-718. 





Drugability of opioid peptides: one global  score which includes different characteristics.            
Drugability reflected in a desirability value: 
 
•  Receptor affinity: KD 
 
•  Metabolic stability: plasma vs. brain 
 
•  BBB behavior: influx vs. efflux 
IN VIVO 
 
S. Van Dorpe et al., J Pept Sci, 17 (2011) 398-404. 
Peptide D-value Ranking 
SB Aba 0.956 1 
P41 0.929 2 
P42 0.867 3 
Dermorphin 0.711 4 
EM-1 0.566 5 
EM-2 0.551 6 
TAPP 0.549 7 
DAMGO 0.486 8 
CTOP 0.448 9 
TAPS 0.422 10 
P43 0.224 11 









A. Novoa et al., J Med Chem, 2012, submitted.  























































334 therapeutic peptides  
Challenge for opioid peptides:  








2.    TO STORE IN THE HIPPOCAMPUS (long-term memory) 
 
• Dissection of pharmacological roles and interplay of “systems” (pain-
immune) 
 
• Receptor affinity and selectivity (biological activity): message-address 
related, as well as metabolic stability and BBB behavior 
=> DRUGABILITY 
 
• Quality and stability of peptides is an important aspect to avoid false 
functionality conclusions in opioid-peptide research 
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I am sorry, you 
cannot enter 
the brain! 
To the brain 
 
 
